RecruitingPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Sponsor

IDEAYA Biosciences

Enrollment

260 participants

Start Date

Mar 4, 2026

Study Type

INTERVENTIONAL

Conditions

Gastric Adenocarcinoma Bladder Cancer Mesothelioma Urothelial Carcinoma (UC)Pleural Mesothelioma NSCLC Adenocarcinoma Gastroesophageal Cancer (GC)Adenocarcinoma of Esophagus Squamous Cell Car. - Esophagus Peritoneal Mesothelioma

Summary

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new drug called IDE892 — alone or in combination — for people with advanced cancers that have a specific genetic change called MTAP deletion. This includes certain lung cancers, bladder cancers, mesothelioma, and stomach/esophageal cancers. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic cancer with a confirmed MTAP gene deletion - Your cancer has progressed after at least one prior treatment - Your cancer can be measured on a scan - You are in good physical condition (ECOG 0 or 1) - You have adequate blood counts and organ function **You may NOT be eligible if...** - You have active brain metastases requiring high-dose steroids - You have had another cancer in the past 2 years (with some exceptions) - You have serious heart disease - You have had recent severe infections, active hepatitis, or HIV - You were on certain common medications (like proton pump inhibitors) in the past week - You have not recovered from side effects of previous treatments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIDE892

IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions.

DRUGIDE397

IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors.